ArticleTranslational psychiatry2022
Oxytocin and orexin systems bidirectionally regulate the ability of opioid cues to bias reward seeking.
Article in Translational psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Improving translational insight using sequential sampling models in drug choice.Psychopharmacology · 2026Review
- Decreased Oxytocin Mediates PVN-CA2 and PVN-PrL in Sleep Deprivation-Induced Social Memory Deficits.Research (Washington, D.C.) · 2026Article
- Chemogenetic Inhibition and Optogenetic Depotentiation of the Prelimbic Cortex to Paraventricular Thalamus Pathway Attenuate Abstinence-Induced Plasticity and Heroin Seeking in Rats.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
- Characterization of a rat model expressing Cre recombinase in oxytocinergic neurons: NTac:SD-OxtNeuroscience · 2025Article
- Found in translation: orexin receptor antagonism for the treatment of opioid use disorder.Translational psychiatry · 2025Review
- A Review of Behavioral Economic Manipulations Affecting Drug versus Nondrug Choice in Rats.Perspectives on behavior science · 2025Review
- Emerging medications and pharmacological treatment approaches for substance use disorders.Pharmacology, biochemistry, and behavior · 2025Review
- Oxytocin modulates inhibitory balance in the prelimbic cortex to support social memory consolidation during REM sleep.Theranostics · 2025Article
- The psychedelic drug DOI reduces heroin motivation by targeting 5-HT2A receptors in a heroin and alcohol co-use model.Neuropharmacology · 2024Article
- Contribution of hypothalamic orexin (hypocretin) circuits to pathologies of motivation.British journal of pharmacology · 2024Review
- The central oxytocinergic system of the prairie vole.Brain structure & function · 2024Article
- Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial.EClinicalMedicine · 2023Article
- Tabernanthalog Reduces Motivation for Heroin and Alcohol in a Polydrug Use Model.Psychedelic medicine (New Rochelle, N.Y.) · 2023Article
- Binge eating, overeating and food addiction: Approaches for examining food overconsumption in laboratory rodents.Progress in neuro-psychopharmacology & biological psychiatry · 2023Review
- Comparison of binge-eating disorder and food addiction.The Journal of international medical research · 2023Review
- Neural circuits controlling choice behavior in opioid addiction.Neuropharmacology · 2023Review
- Animal models of compulsion alcohol drinking: Why we love quinine-resistant intake and what we learned from it.Frontiers in psychiatry · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
As opioid-related fatalities continue to rise, the need for novel opioid use disorder (OUD) treatments could not be more urgent. Two separate hypothalamic neuropeptide systems have shown promise in preclinical OUD models. The oxytocin system, originating in the paraventricular nucleus (PVN), may protect against OUD severity. By contrast, the orexin system, originating in the lateral hypothalamus (LH), may exacerbate OUD severity. Thus, activating the oxytocin system or inhibiting the orexin system are potential therapeutic strategies. The specific role of these systems with regard to specific OUD outcomes, however, is not fully understood. Here, we probed the therapeutic efficacy of pharmacological interventions targeting the orexin or oxytocin system on two distinct metrics of OUD severity in rats-heroin choice (versus choice for natural reward, i.e., food) and cued reward seeking. Using a preclinical model that generates approximately equal choice between heroin and food reward, we examined the impact of exogenously administered oxytocin, an oxytocin receptor antagonist (L-368,899), and a dual orexin receptor antagonist (DORA-12) on opioid choice. Whereas these agents did not alter heroin choice when rewards (heroin and food) were available, oxytocin and DORA-12 each significantly reduced heroin seeking in the presence of competing reward cues when no rewards were available. In addition, the number of LH orexin neurons and PVN oxytocin neurons correlated with specific behavioral economic variables indicative of heroin versus food motivation. These data identify a novel bidirectional role of the oxytocin and orexin systems in the ability of opioid-related cues to bias reward seeking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.